<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366143</url>
  </required_header>
  <id_info>
    <org_study_id>GO29436</org_study_id>
    <secondary_id>2014-003207-30</secondary_id>
    <nct_id>NCT02366143</nct_id>
  </id_info>
  <brief_title>A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <acronym>IMpower150</acronym>
  <official_title>A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an&#xD;
      engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with&#xD;
      carboplatin+paclitaxel with or without bevacizumab compared with treatment with&#xD;
      carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV&#xD;
      non-squamous NSCLC. Participants were randomized in a 1:1:1 ratio to Arm A&#xD;
      (Atezolizumab+Carboplatin+Paclitaxel), Arm B&#xD;
      (Atezolizumab+Carboplatin+Paclitaxel+Bevacizumab), or Arm C&#xD;
      (Carboplatin+Paclitaxel+Bevacizumab).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2015</start_date>
  <completion_date type="Actual">December 7, 2020</completion_date>
  <primary_completion_date type="Actual">September 13, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population</measure>
    <time_frame>Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)</time_frame>
    <description>Progression Free Survival (PFS), as Determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population</measure>
    <time_frame>Baseline until death until data cut-off on 22 January 2018 (up to approximately 34 months)</time_frame>
    <description>Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population</measure>
    <time_frame>Baseline until death (up approximately 53 months)</time_frame>
    <description>Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS, as Determined by the Independent Review Facility (IRF) in Arm B Versus Arm C in Teff-High-WT Population and ITT-WT Population</measure>
    <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
    <description>PFS, as determined by the independent review facility (IRF) Using RECIST v1.1 in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS, as Determined by the Investigator in Arm B Versus Arm C in Teff High Population and ITT Population</measure>
    <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
    <description>PFS, as determined by the investigator according to RECIST v1.1, in Arm B versus C in the Teff high population and ITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS, as Determined by the Investigator in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population</measure>
    <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
    <description>PFS, as determined by the investigator according to RECIST v1.1, in Arm A versus B in the Teff high-WT population and ITT-WT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS, as Determined by the Investigator in Arm B Versus Arm C by PD-L1 Subgroup</measure>
    <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
    <description>PFS as Determined by the Investigator according to RECIST v1.1, in Arm B Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in Arm B Versus Arm C by PD-L1 Subgroup</measure>
    <time_frame>Baseline until death (up to approximately 34 months)</time_frame>
    <description>OS in Arm B Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in Arm A Versus Arm C by PD-L1 Subgroup</measure>
    <time_frame>Baseline until death (up approximately 53 months)</time_frame>
    <description>OS in Arm A Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in Arm B Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population</measure>
    <time_frame>Baseline until death (up to approximately 34 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in Arm A Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population</measure>
    <time_frame>Baseline until death (up approximately 53 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population</measure>
    <time_frame>Baseline until death (up approximately 53 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR), as Determined By Investigator in Arm B Versus Arm C</measure>
    <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
    <description>DOR, as determined by investigator according to RECIST v1.1 in Arm B versus Arm C in the Teff high-WT population and the ITT-WT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator in the Teff-High-WT Population and ITT-WT Population</measure>
    <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
    <description>Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator using RECIST v1.1 in the Teff-High-WT population and ITT-WT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rates at Years 1 and 2 in Arm B Versus Arm C</measure>
    <time_frame>Baseline to 2 years or death, whichever occurs first.</time_frame>
    <description>OS at 1- and 2-year landmark timepoints in Teff-high WT population and ITT-WT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rates at Years 1 and 2 in Arm A Versus Arm C</measure>
    <time_frame>Baseline to 2 years or death, whichever occurs first.</time_frame>
    <description>OS at 1- and 2-year landmark timepoints in Teff-high WT population and ITT-WT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms Determined by European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Score</measure>
    <time_frame>Baseline up to approximately 29 months</time_frame>
    <description>EORTC QLQ-C30 is a validated &amp; reliable self-report measure (Aaronson et al.1993;Fitzsimmons et al.1999) that consists of 30 questions that assess 5 aspects of patient functioning (physical,emotional,role, cognitive,and social), 3 symptom scales (fatigue,nausea &amp; vomiting, pain),global health/quality of life,and six single items (dyspnea,insomnia, appetite loss,constipation,diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life);however a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al.1998).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score</measure>
    <time_frame>Baseline up to approximately 29 months</time_frame>
    <description>QLQ-LC13 Quality-of-Life Questionnaire Lung Cancer Module incorporates one multiple-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale</measure>
    <time_frame>Baseline up to approximately 29 months</time_frame>
    <description>The SILC (Symptoms in Lung Cancer) scale was used to assess patient-reported severity of lung cancer symptoms (chest pain, dyspnea, and cough). The SILC scale is a 9-item content validated self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a symptom severity score. The SILC questionnaire comprises three individual symptoms (dyspnea, cough, chest pain) and are scored at the individual symptom level, thus have a dyspnea score, chest pain score, and cough score. Each individual symptom score is calculated as the average of responses for the symptom items [e.g. Chest Pain Score=mean (item 1; item 2)]. An increase in score is suggestive of a worsening in symptomology (i.e. frequency or severity). A score change of ≥0.3 points for the dyspnea and cough symptom scores is considered to be clinically significant; whereas a score change of ≥0.5 points for the chest pain score is considered to be clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Baseline up to data cutoff date 7 December 2020 (up to approximately 68 months)</time_frame>
    <description>Percentage of participants with at least one adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab</measure>
    <time_frame>Baseline up to approximately 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of Atezolizumab in Arm A and Arm B</measure>
    <time_frame>Day 1 of Cycle 1 and 3 (Cycle length=21 days)</time_frame>
    <description>The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Arm A and Arm B</measure>
    <time_frame>Day 21 of Cycles 1, 2 3, and 7 (Cycle length=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations for Carboplatin in Arm A, Arm B, and Arm C</measure>
    <time_frame>Predose (same day of treatment administration), 5-10 minutes before end of carboplatin infusion, 1 h after carboplatin infusion (infusion duration=15 to 30 minutes) on D1 of Cy1,3 (Cycle length=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations for Paclitaxel in Arm A, Arm B, and Arm C</measure>
    <time_frame>Predose (same day of treatment administration), 5-10 minutes before end of paclitaxel infusion, 1 h after paclitaxel infusion (infusion duration=3 h) on D1 of Cy1,3 (Cycle length=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Bevacizumab in Arm B and Arm C</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of Bevacizumab in Arm B and Arm C</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 2 Day 21 (Cycle length=21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1202</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody</intervention_name>
    <description>Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.</description>
    <arm_group_label>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</arm_group_label>
    <arm_group_label>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</arm_group_label>
    <other_name>MPDL3280A</other_name>
    <other_name>RO5541267</other_name>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.</description>
    <arm_group_label>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</arm_group_label>
    <arm_group_label>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.</description>
    <arm_group_label>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</arm_group_label>
    <arm_group_label>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</arm_group_label>
    <arm_group_label>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.</description>
    <arm_group_label>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</arm_group_label>
    <arm_group_label>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</arm_group_label>
    <arm_group_label>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0 or 1&#xD;
&#xD;
          -  Histologically or cytologically confirmed, Stage IV non-squamous NSCLC&#xD;
&#xD;
          -  Participants with no prior treatment for Stage IV non-squamous NSCLC&#xD;
&#xD;
          -  Known PD-L1 status as determined by immunohistochemistry assay performed on previously&#xD;
             obtained archival tumor tissue or tissue obtained from a biopsy at screening&#xD;
&#xD;
          -  Measurable disease as defined by RECIST v1.1&#xD;
&#xD;
          -  Adequate hematologic and end organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cancer-Specific Exclusions:&#xD;
&#xD;
          -  Active or untreated central nervous system metastases&#xD;
&#xD;
          -  Malignancies other than NSCLC within 5 years prior to randomization, with the&#xD;
             exception of those with a negligible risk of metastasis or death treated with expected&#xD;
             curative outcome&#xD;
&#xD;
        General Medical Exclusions:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest computed tomography scan. History of radiation pneumonitis in the radiation&#xD;
             field (fibrosis) is permitted&#xD;
&#xD;
          -  Positive test for human immunodeficiency virus&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C&#xD;
&#xD;
          -  Severe infection within 4 weeks prior to randomization&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Illness or condition that interferes with the participant's capacity to understand,&#xD;
             follow and/or comply with study procedures&#xD;
&#xD;
        Exclusion Criteria Related to Medications:&#xD;
&#xD;
          -  Prior treatment with cluster of differentiation 137 agonists or immune checkpoint&#xD;
             blockade therapies, anti-programmed death-1, and anti-PD-L1 therapeutic antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ironwood Cancer &amp; Research Centers</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Flagstaff</city>
        <state>Arizona</state>
        <zip>86001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern CA Permanente Med Grp</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marin Cancer Care Inc</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Health</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center UCI</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Lonetree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital Inc</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida - Baptist South</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of the Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Cancer Institute, PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists, S.C.</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology; Associates of the Quad Cities</name>
      <address>
        <city>Bettendorf</city>
        <state>Iowa</state>
        <zip>52722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialists</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Regional Cancer Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicolett - Frauenshuh Cancer Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Specialists</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Hospital; Oncology Research</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates LLC</name>
      <address>
        <city>Sewell</city>
        <state>New Jersey</state>
        <zip>08080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Health of the Carolinas</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45203-0542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy St Anne Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bend Memorial Clinic</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Charles Medical Center Bend; Cancer Care Of The Cascades</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Insitute and Research Center</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Care Associates</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pittsburgh Medical Ctr</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialists</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Cancer Care</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Regional Cancer Center - Auburn</name>
      <address>
        <city>Auburn</city>
        <state>Washington</state>
        <zip>98002-4117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Regional Cancer Partnership</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University; Mary Babb Randolph Can Ctr</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Austral</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1019</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación CENIT para la Investigación en Neurociencias</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1125ABD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral (CORI)</name>
      <address>
        <city>La Rioja</city>
        <zip>F5300COE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial del Centenario</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Koriza</name>
      <address>
        <city>Santa Rosa</city>
        <zip>6300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion; Clinica - Clinica Viedma S.A.</name>
      <address>
        <city>Viedma</city>
        <zip>R8500ACE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Cancer Care Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital; Department of Medical Oncology</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4810</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide Cancer Centre</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Launceston General Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital Malvern</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Prahan</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medizinische Privatuniversität</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ste-Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CETUS Hospital Dia Oncologia</name>
      <address>
        <city>Uberaba</city>
        <state>MG</state>
        <zip>38082-049</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Do Cancer Delondrina_X; Unidade De Pesquisa Clinica</name>
      <address>
        <city>Londrina</city>
        <state>PR</state>
        <zip>86 015 520</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liga Norte Riograndense Contra O Câncer</name>
      <address>
        <city>Natal</city>
        <state>RN</state>
        <zip>59040150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPCEM; Instituto de Pesquisa de Estudos Multicêntricos</name>
      <address>
        <city>Caxias do Sul</city>
        <state>RS</state>
        <zip>95070-560</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mae de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cancer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Ribeirãopretano de Combate Ao Câncer; Centro Especializado De Oncologia</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>SP</state>
        <zip>14015-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de Sao Jose do Rio Preto</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital A. C. Camargo; Oncologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01509-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Central Onco Hospital OOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Serdika, EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Center</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Santa Maria</name>
      <address>
        <city>Santiago</city>
        <zip>0</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health &amp; Care SPA</name>
      <address>
        <city>Santiago</city>
        <zip>7500006</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedad de Investigaciones Medicas Ltda (SIM)</name>
      <address>
        <city>Temuco</city>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Nord AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie Centre Hospitalier Régional La Réunion Site Felix Guyon</name>
      <address>
        <city>Saint Denis Cedex</city>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Saint Quentin</name>
      <address>
        <city>Saint Quentin</city>
        <zip>2100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Toulon - La Seyne sur Mer</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées de Sainte Anne; Service de Pneumologie</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey;Université Paul Sabatier</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Emil von Behring GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev.Krankenhaus Bielefeld gGmbH; Klinik für Innere Medizin und Geriatrie</name>
      <address>
        <city>Bielefeld</city>
        <zip>33611</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta Kranken-Anstalt gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum &quot;Carl Gustav Carus&quot; der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabethen Krankenhaus</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LungenClinic Großhansdorf GmbH</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria; Halle-Dolau gGmbH</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Des Saarlandes; Klinik für Innere Medizin V</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Koln gGmbH; Lungenklinik Onkologische Ambulanz</name>
      <address>
        <city>Koln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Loewenstein gGmbH; Onk &amp; Pal</name>
      <address>
        <city>Loewenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bogenhausen</name>
      <address>
        <city>München</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Bruder Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftung Mathias-Spital Rheine</name>
      <address>
        <city>Rheine</city>
        <zip>48431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AORN A Cardarelli</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica Del S Cuore</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per la Ricerca sul Cancro di Genova</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL 3 Genovese; DSM</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Unita Sanitaria Locale N1 Sassari; Unita Operativa Di Oncologia Medica</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Versilia</name>
      <address>
        <city>Lido Di Camaiore</city>
        <state>Toscana</state>
        <zip>55043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile - Livorno</name>
      <address>
        <city>Livorno</city>
        <state>Toscana</state>
        <zip>57124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Ehime</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Center</name>
      <address>
        <city>Kanagawa</city>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center</name>
      <address>
        <city>Miyagi</city>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka Toneyama Medical Center</name>
      <address>
        <city>Osaka</city>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>162-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical University Hospital Latvian Oncology Centre</name>
      <address>
        <city>Riga</city>
        <zip>LV-1079</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Rīga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Vilnius</city>
        <zip>08660</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Universitario Contra El Cancer</name>
      <address>
        <city>Monterrey</city>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancerologia de Queretaro</name>
      <address>
        <city>Queretaro</city>
        <zip>76090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hemato Oncologico Privado; Oncologia</name>
      <address>
        <city>Toluca</city>
        <zip>50080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'S Hertogenbosch</city>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC Location VUMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis; Afdeling Longziekten</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>EDE</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooiziekenhuizen</name>
      <address>
        <city>Hilversum</city>
        <zip>1201 DA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis; Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis; R&amp;D Long</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC; Afdeling Longziekten</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen, Zutphen</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Monte Carmelo</name>
      <address>
        <city>Arequipa</city>
        <zip>04001</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Especializado de Enfermedades Neoplásicas</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <zip>Lima 34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar E Universitário de Coimbra EPE</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-602</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues Oncologia de Lisboa Francisco Gentil EPE</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pulido Valente; Servico de Pneumologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1796-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto - Hospital de Santo António</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sao Joao; Servico de Pneumologia</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Oncology Hospital #62</name>
      <address>
        <city>Moscovskaya Oblast</city>
        <state>Moskovskaja Oblast</state>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Oncology Research Center n.a. N.N. Blokhin</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evromedservis LCC</name>
      <address>
        <city>Pushkin</city>
        <zip>196603</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Oncology Dispensary</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre; Medical Oncology</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny onkologicky ustav</name>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>POKO Poprad s.r.o.</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli; Servicio de Oncologia</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>8208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>LAS Palmas</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario U. de Ourense</name>
      <address>
        <city>Ourense</city>
        <state>Orense</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lluis Alcanyis De Xativa</name>
      <address>
        <city>Xativa</city>
        <state>Valencia</state>
        <zip>46800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lucus Augusti; Servicio de Oncologia</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>280146</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro-CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland</name>
      <address>
        <city>Bruderholz</city>
        <zip>4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital Sursee</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen; Onkologie/Hämatologie</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital; Hematology-Oncology</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital; Department of Urology</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center Liou Ying Campus</name>
      <address>
        <city>Liuying Township</city>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital Chiayi</name>
      <address>
        <city>Putzu</city>
        <zip>613</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung Univ Hosp</name>
      <address>
        <city>Tainan</city>
        <zip>00704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan Uni Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10041</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation Linkou Branch</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Xitun Dist.</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ME Bukovinian Clinical Oncology Center</name>
      <address>
        <city>Chernivtsi</city>
        <state>Chernihiv Governorate</state>
        <zip>58013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution City Clinical Hospital #4 of Dnipro City Council - PPDS; Dept of Chemotherapy</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Katerynoslav Governorate</state>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhgorod Central City Clinical Hospital</name>
      <address>
        <city>Uzhhorod</city>
        <state>Katerynoslav Governorate</state>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MNPE Zaporizhzhia Regional Antitumor Center ZRC</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Katerynoslav Governorate</state>
        <zip>69040</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkiv Governorate</state>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MNPE Transcarpathian Antitumor Center of the Transcarpathian Regional Council; Chemotherapy Dept</name>
      <address>
        <city>Uzhhorod</city>
        <state>Kherson Governorate</state>
        <zip>88014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution SubCarpathian Clinical Oncological Centre; Surgical department#2</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>KIEV Governorate</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council</name>
      <address>
        <city>Vinnytsia</city>
        <state>KIEV Governorate</state>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Institute of Medical Radiology n.a. S.P. Hryhoriev of NAMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department</name>
      <address>
        <city>Kryvyi Rih</city>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncological Center</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poltava Regional Clinical Oncology Dispensary of Poltava Regional Council; Thoracic department</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Sumy</city>
        <zip>40005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <results_first_submitted>August 21, 2020</results_first_submitted>
  <results_first_submitted_qc>October 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 27, 2020</results_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02366143/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02366143/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm C</title>
          <description>Bevacizumab+Paclitaxel+Carboplatin</description>
        </group>
        <group group_id="P2">
          <title>Arm B</title>
          <description>Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin</description>
        </group>
        <group group_id="P3">
          <title>Arm A</title>
          <description>Atezolizumab+Paclitaxel+Carboplatin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
                <participants group_id="P2" count="400"/>
                <participants group_id="P3" count="402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
                <participants group_id="P2" count="400"/>
                <participants group_id="P3" count="402"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="278"/>
                <participants group_id="P3" count="280"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor request to withdraw/discontinue patient</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Increased Microscopic RBCS on Urinalysis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization Error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PI Move and Site Closure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor request to withdraw/discontinue patient in survival follow up</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moved to roll-over study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moved to commercial stock</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient stopped treatment due to disease progression;didn't enter follow up due to study termination</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient rolling over to patient assistance program</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient continue same treatment via Post Trial Access Progarm (PTAP)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requester's instructions</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Uneligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Post Trial Migration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moving onto PTAP commercial stock</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient switched to PTAP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moved to commercial atezolizumab use</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm C</title>
          <description>Bevacizumab+Paclitaxel+Carboplatin</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin</description>
        </group>
        <group group_id="B3">
          <title>Arm A</title>
          <description>Atezolizumab+Paclitaxel+Carboplatin</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="400"/>
            <count group_id="B2" value="400"/>
            <count group_id="B3" value="402"/>
            <count group_id="B4" value="1202"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="9.3"/>
                    <measurement group_id="B2" value="63.0" spread="9.5"/>
                    <measurement group_id="B3" value="62.3" spread="9.2"/>
                    <measurement group_id="B4" value="62.8" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="161"/>
                    <measurement group_id="B4" value="482"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="241"/>
                    <measurement group_id="B4" value="720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="335"/>
                    <measurement group_id="B2" value="322"/>
                    <measurement group_id="B3" value="331"/>
                    <measurement group_id="B4" value="988"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population</title>
        <description>Progression Free Survival (PFS), as Determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population.</description>
        <time_frame>Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)</time_frame>
        <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population</title>
          <description>Progression Free Survival (PFS), as Determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population.</description>
          <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="9.1" upper_limit="13.0"/>
                    <measurement group_id="O2" value="6.8" lower_limit="5.9" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="356"/>
                    <count group_id="O2" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="7.7" upper_limit="9.8"/>
                    <measurement group_id="O2" value="6.8" lower_limit="6.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ITT-WT population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Teff-high WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population</title>
        <description>Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population</description>
        <time_frame>Baseline until death until data cut-off on 22 January 2018 (up to approximately 34 months)</time_frame>
        <population>ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population</title>
          <description>Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population</description>
          <population>ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="17.0" upper_limit="23.8"/>
                    <measurement group_id="O2" value="14.7" lower_limit="13.3" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0164</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population</title>
        <description>Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population</description>
        <time_frame>Baseline until death (up approximately 53 months)</time_frame>
        <population>ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population</title>
          <description>Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population</description>
          <population>ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="15.7" upper_limit="21.5"/>
                    <measurement group_id="O2" value="14.7" lower_limit="12.9" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0528</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.842</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.707</ci_lower_limit>
            <ci_upper_limit>1.002</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS, as Determined by the Independent Review Facility (IRF) in Arm B Versus Arm C in Teff-High-WT Population and ITT-WT Population</title>
        <description>PFS, as determined by the independent review facility (IRF) Using RECIST v1.1 in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population.</description>
        <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
        <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS, as Determined by the Independent Review Facility (IRF) in Arm B Versus Arm C in Teff-High-WT Population and ITT-WT Population</title>
          <description>PFS, as determined by the independent review facility (IRF) Using RECIST v1.1 in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population.</description>
          <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="8.4" upper_limit="13.0"/>
                    <measurement group_id="O2" value="7.0" lower_limit="6.1" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="356"/>
                    <count group_id="O2" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="7.7" upper_limit="9.7"/>
                    <measurement group_id="O2" value="7.0" lower_limit="6.3" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ITT-WT population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Teff-high WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.564</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.418</ci_lower_limit>
            <ci_upper_limit>0.760</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS, as Determined by the Investigator in Arm B Versus Arm C in Teff High Population and ITT Population</title>
        <description>PFS, as determined by the investigator according to RECIST v1.1, in Arm B versus C in the Teff high population and ITT population.</description>
        <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
        <population>Teff-high population is defined as the patients in the ITT population with Teff signature expression &gt;=-1.91. ITT population is defined as all randomized patients, regardless of receipt of the assigned treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS, as Determined by the Investigator in Arm B Versus Arm C in Teff High Population and ITT Population</title>
          <description>PFS, as determined by the investigator according to RECIST v1.1, in Arm B versus C in the Teff high population and ITT population.</description>
          <population>Teff-high population is defined as the patients in the ITT population with Teff signature expression &gt;=-1.91. ITT population is defined as all randomized patients, regardless of receipt of the assigned treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Teff-high Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="9.1" upper_limit="13.0"/>
                    <measurement group_id="O2" value="6.8" lower_limit="5.8" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="7.9" upper_limit="9.8"/>
                    <measurement group_id="O2" value="6.8" lower_limit="6.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Teff-high Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.492</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.374</ci_lower_limit>
            <ci_upper_limit>0.649</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ITT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.610</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.517</ci_lower_limit>
            <ci_upper_limit>0.720</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS, as Determined by the Investigator in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population</title>
        <description>PFS, as determined by the investigator according to RECIST v1.1, in Arm A versus B in the Teff high-WT population and ITT-WT population.</description>
        <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
        <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS, as Determined by the Investigator in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population</title>
          <description>PFS, as determined by the investigator according to RECIST v1.1, in Arm A versus B in the Teff high-WT population and ITT-WT population.</description>
          <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Teff-high WT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="5.6" upper_limit="7.8"/>
                    <measurement group_id="O2" value="11.3" lower_limit="9.1" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT-WT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="356"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="5.6" upper_limit="7.0"/>
                    <measurement group_id="O2" value="8.3" lower_limit="7.7" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS, as Determined by the Investigator in Arm B Versus Arm C by PD-L1 Subgroup</title>
        <description>PFS as Determined by the Investigator according to RECIST v1.1, in Arm B Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)</description>
        <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
        <population>The PD-L1-selected WT populations are defined as the PD-L1-selected populations (TC2/3 or IC2/3 population or TC1/2/3 or IC1/2/3 population) excluding patients with a sensitizing EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS, as Determined by the Investigator in Arm B Versus Arm C by PD-L1 Subgroup</title>
          <description>PFS as Determined by the Investigator according to RECIST v1.1, in Arm B Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)</description>
          <population>The PD-L1-selected WT populations are defined as the PD-L1-selected populations (TC2/3 or IC2/3 population or TC1/2/3 or IC1/2/3 population) excluding patients with a sensitizing EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC2/3 or IC2/3 Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="8.3" upper_limit="13.0"/>
                    <measurement group_id="O2" value="6.8" lower_limit="5.8" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC1/2/3 or IC1/2/3 Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="8.3" upper_limit="12.5"/>
                    <measurement group_id="O2" value="6.8" lower_limit="5.8" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TC2/3 or IC2/3 Subgroup</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.471</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.352</ci_lower_limit>
            <ci_upper_limit>0.647</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TC1/2/3 or IC1/2/3 Subgroup</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.486</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.386</ci_lower_limit>
            <ci_upper_limit>0.639</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in Arm B Versus Arm C by PD-L1 Subgroup</title>
        <description>OS in Arm B Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)</description>
        <time_frame>Baseline until death (up to approximately 34 months)</time_frame>
        <population>The PD-L1-selected WT populations are defined as the PD-L1-selected populations (TC2/3 or IC2/3 population or TC1/2/3 or IC1/2/3 population) excluding patients with a sensitizing EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>OS in Arm B Versus Arm C by PD-L1 Subgroup</title>
          <description>OS in Arm B Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)</description>
          <population>The PD-L1-selected WT populations are defined as the PD-L1-selected populations (TC2/3 or IC2/3 population or TC1/2/3 or IC1/2/3 population) excluding patients with a sensitizing EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC 2/3 or IC2/3 Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="17.0" upper_limit="26.1"/>
                    <measurement group_id="O2" value="16.7" lower_limit="10.5" upper_limit="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC1/2/3 or IC1/2/3 Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="18.2" upper_limit="26.1"/>
                    <measurement group_id="O2" value="16.4" lower_limit="11.2" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TC2/3 or IC2/3, WT ITT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Unstratified Analysis</non_inferiority_desc>
            <p_value>0.2765</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.824</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.580</ci_lower_limit>
            <ci_upper_limit>1.169</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TC1/2/3 or IC1/2/3, WT ITT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Unstratified Analysis</non_inferiority_desc>
            <p_value>0.0829</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.771</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.575</ci_lower_limit>
            <ci_upper_limit>1.035</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in Arm A Versus Arm C by PD-L1 Subgroup</title>
        <description>OS in Arm A Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)</description>
        <time_frame>Baseline until death (up approximately 53 months)</time_frame>
        <population>PD-L1 WT populations are defined as the PD-L1 populations (TC2/3 or IC2/3 population or TC1/2/3 or IC1/2/3 population) excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>OS in Arm A Versus Arm C by PD-L1 Subgroup</title>
          <description>OS in Arm A Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)</description>
          <population>PD-L1 WT populations are defined as the PD-L1 populations (TC2/3 or IC2/3 population or TC1/2/3 or IC1/2/3 population) excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC2/3 or IC2/3 Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="20.5" upper_limit="40.0"/>
                    <measurement group_id="O2" value="17.0" lower_limit="10.3" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC1/2/3 or IC1/2/3 Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="20.2" upper_limit="28.1"/>
                    <measurement group_id="O2" value="16.0" lower_limit="11.2" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TC1/2/3 or IC1/2/3 ITT-WT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Unstratified Analysis</non_inferiority_desc>
            <p_value>0.0073</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.709</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.551</ci_lower_limit>
            <ci_upper_limit>0.913</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TC2/3 or IC2/3 Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Unstratified Analysis</non_inferiority_desc>
            <p_value>0.0097</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.662</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.484</ci_lower_limit>
            <ci_upper_limit>0.907</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in Arm B Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population</title>
        <time_frame>Baseline until death (up to approximately 34 months)</time_frame>
        <population>Teff-high WT population, defined as the Teff-high population excluding patients with activating EGFR mutation or ALK translocation. Teff-high population, defined as participants in the ITT population with Teff signature expression &gt;=-1.91. ITT population, defined as all randomized patients, regardless of receipt of the assigned treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>OS in Arm B Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population</title>
          <population>Teff-high WT population, defined as the Teff-high population excluding patients with activating EGFR mutation or ALK translocation. Teff-high population, defined as participants in the ITT population with Teff signature expression &gt;=-1.91. ITT population, defined as all randomized patients, regardless of receipt of the assigned treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Teff High-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="156"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="17.8" upper_limit="NA">Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="16.7" lower_limit="12.4" upper_limit="NA">Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Teff High Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" lower_limit="19.1" upper_limit="NA">Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="16.7" lower_limit="12.4" upper_limit="NA">Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="17.4" upper_limit="24.2"/>
                    <measurement group_id="O2" value="14.9" lower_limit="13.4" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Teff high-WT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.2843</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.831</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.592</ci_lower_limit>
            <ci_upper_limit>1.167</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Teff high</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.1861</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.802</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.579</ci_lower_limit>
            <ci_upper_limit>1.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ITT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0060</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.764</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.630</ci_lower_limit>
            <ci_upper_limit>0.926</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in Arm A Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population</title>
        <time_frame>Baseline until death (up approximately 53 months)</time_frame>
        <population>Teff-high WT population, defined as Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. Teff-high population, defined as patients in the ITT population with Teff signature expression &gt;=-1.91. ITT population is defined as all randomized patients, regardless of receipt of the assigned treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>OS in Arm A Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population</title>
          <population>Teff-high WT population, defined as Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. Teff-high population, defined as patients in the ITT population with Teff signature expression &gt;=-1.91. ITT population is defined as all randomized patients, regardless of receipt of the assigned treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="163"/>
                    <count group_id="O2" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" lower_limit="17.6" upper_limit="26.3"/>
                    <measurement group_id="O2" value="16.3" lower_limit="11.2" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Teff-high Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="17.1" upper_limit="26.0"/>
                    <measurement group_id="O2" value="16.7" lower_limit="11.4" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="402"/>
                    <count group_id="O2" value="400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="16.3" upper_limit="21.5"/>
                    <measurement group_id="O2" value="15.0" lower_limit="13.4" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Teff high-WT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0894</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.786</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.595</ci_lower_limit>
            <ci_upper_limit>1.038</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Teff high</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.1276</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.815</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.626</ci_lower_limit>
            <ci_upper_limit>1.061</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ITT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0681</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.861</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.733</ci_lower_limit>
            <ci_upper_limit>1.011</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population</title>
        <time_frame>Baseline until death (up approximately 53 months)</time_frame>
        <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>OS in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population</title>
          <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Teff High-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="163"/>
                    <count group_id="O2" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" lower_limit="17.6" upper_limit="26.3"/>
                    <measurement group_id="O2" value="25.8" lower_limit="19.1" upper_limit="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="350"/>
                    <count group_id="O2" value="359"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="15.7" upper_limit="21.5"/>
                    <measurement group_id="O2" value="19.5" lower_limit="17.0" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Teff high-WT ITT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.4599</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.901</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.683</ci_lower_limit>
            <ci_upper_limit>1.188</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR), as Determined By Investigator in Arm B Versus Arm C</title>
        <description>DOR, as determined by investigator according to RECIST v1.1 in Arm B versus Arm C in the Teff high-WT population and the ITT-WT population.</description>
        <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
        <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR), as Determined By Investigator in Arm B Versus Arm C</title>
          <description>DOR, as determined by investigator according to RECIST v1.1 in Arm B versus Arm C in the Teff high-WT population and the ITT-WT population.</description>
          <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Teff high-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="9.7" upper_limit="15.7"/>
                    <measurement group_id="O2" value="5.7" lower_limit="4.9" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="6.9" upper_limit="11.4"/>
                    <measurement group_id="O2" value="5.7" lower_limit="5.1" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ITT-WT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.523</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.406</ci_lower_limit>
            <ci_upper_limit>0.675</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Teff-high WT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.420</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.283</ci_lower_limit>
            <ci_upper_limit>0.624</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator in the Teff-High-WT Population and ITT-WT Population</title>
        <description>Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator using RECIST v1.1 in the Teff-High-WT population and ITT-WT population.</description>
        <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)</time_frame>
        <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator in the Teff-High-WT Population and ITT-WT Population</title>
          <description>Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator using RECIST v1.1 in the Teff-High-WT population and ITT-WT population.</description>
          <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="353"/>
                <count group_id="O3" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0"/>
                    <measurement group_id="O2" value="69.3"/>
                    <measurement group_id="O3" value="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="353"/>
                    <count group_id="O3" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3"/>
                    <measurement group_id="O2" value="63.5"/>
                    <measurement group_id="O3" value="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS Rates at Years 1 and 2 in Arm B Versus Arm C</title>
        <description>OS at 1- and 2-year landmark timepoints in Teff-high WT population and ITT-WT population.</description>
        <time_frame>Baseline to 2 years or death, whichever occurs first.</time_frame>
        <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>OS Rates at Years 1 and 2 in Arm B Versus Arm C</title>
          <description>OS at 1- and 2-year landmark timepoints in Teff-high WT population and ITT-WT population.</description>
          <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-Year Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.63" lower_limit="61.28" upper_limit="75.98"/>
                    <measurement group_id="O2" value="58.74" lower_limit="50.03" upper_limit="67.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Year ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.32" lower_limit="62.41" upper_limit="72.22"/>
                    <measurement group_id="O2" value="60.63" lower_limit="55.34" upper_limit="65.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Year Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.03" lower_limit="43.12" upper_limit="60.94"/>
                    <measurement group_id="O2" value="41.70" lower_limit="31.55" upper_limit="51.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Year ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.42" lower_limit="36.94" upper_limit="49.90"/>
                    <measurement group_id="O2" value="33.71" lower_limit="27.44" upper_limit="39.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>1-Year ITT-WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0697</p_value>
            <method>Z-test</method>
            <param_type>Difference in Event Free Rate</param_type>
            <param_value>6.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>13.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-Year ITT-WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0347</p_value>
            <method>Z-test</method>
            <param_type>Difference in Event Free Rate</param_type>
            <param_value>9.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>18.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>1-Year Teff-high WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0890</p_value>
            <method>Z-test</method>
            <param_type>Difference in Event Free Rate</param_type>
            <param_value>9.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.51</ci_lower_limit>
            <ci_upper_limit>21.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-Year Teff-high WT Population</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.1336</p_value>
            <method>Z-test</method>
            <param_type>Difference in Event Free Rate</param_type>
            <param_value>10.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.17</ci_lower_limit>
            <ci_upper_limit>23.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS Rates at Years 1 and 2 in Arm A Versus Arm C</title>
        <description>OS at 1- and 2-year landmark timepoints in Teff-high WT population and ITT-WT population.</description>
        <time_frame>Baseline to 2 years or death, whichever occurs first.</time_frame>
        <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>OS Rates at Years 1 and 2 in Arm A Versus Arm C</title>
          <description>OS at 1- and 2-year landmark timepoints in Teff-high WT population and ITT-WT population.</description>
          <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-Year Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.48" lower_limit="60.29" upper_limit="74.68"/>
                    <measurement group_id="O2" value="56.92" lower_limit="48.32" upper_limit="65.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Year Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.01" lower_limit="38.36" upper_limit="53.66"/>
                    <measurement group_id="O2" value="38.74" lower_limit="30.26" upper_limit="47.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Year ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="222"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.06" lower_limit="59.02" upper_limit="69.11"/>
                    <measurement group_id="O2" value="59.89" lower_limit="54.61" upper_limit="65.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Year ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.45" lower_limit="36.26" upper_limit="46.64"/>
                    <measurement group_id="O2" value="31.79" lower_limit="26.75" upper_limit="36.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>1-Year ITT-WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.2624</p_value>
            <method>Z-test</method>
            <param_type>Difference in Event Free Rate</param_type>
            <param_value>4.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.13</ci_lower_limit>
            <ci_upper_limit>11.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-Year ITT-WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0088</p_value>
            <method>Z-test</method>
            <param_type>Difference in Event Free Rate</param_type>
            <param_value>9.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.43</ci_lower_limit>
            <ci_upper_limit>16.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>1-Year Teff-high WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.0649</p_value>
            <method>Z-test</method>
            <param_type>Difference in Event Free Rate</param_type>
            <param_value>10.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>21.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-Year Teff-high WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.2120</p_value>
            <method>Z-test</method>
            <param_type>Difference in Event Free Rate</param_type>
            <param_value>7.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.15</ci_lower_limit>
            <ci_upper_limit>18.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms Determined by European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Score</title>
        <description>EORTC QLQ-C30 is a validated &amp; reliable self-report measure (Aaronson et al.1993;Fitzsimmons et al.1999) that consists of 30 questions that assess 5 aspects of patient functioning (physical,emotional,role, cognitive,and social), 3 symptom scales (fatigue,nausea &amp; vomiting, pain),global health/quality of life,and six single items (dyspnea,insomnia, appetite loss,constipation,diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life);however a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al.1998).</description>
        <time_frame>Baseline up to approximately 29 months</time_frame>
        <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms Determined by European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Score</title>
          <description>EORTC QLQ-C30 is a validated &amp; reliable self-report measure (Aaronson et al.1993;Fitzsimmons et al.1999) that consists of 30 questions that assess 5 aspects of patient functioning (physical,emotional,role, cognitive,and social), 3 symptom scales (fatigue,nausea &amp; vomiting, pain),global health/quality of life,and six single items (dyspnea,insomnia, appetite loss,constipation,diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life);however a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al.1998).</description>
          <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dyspnea in Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea in ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="356"/>
                    <count group_id="O3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Teff-high WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.6899</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.909</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.571</ci_lower_limit>
            <ci_upper_limit>1.450</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Teff-high WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.1043</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.671</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.413</ci_lower_limit>
            <ci_upper_limit>1.089</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ITT WT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.1730</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.232</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.912</ci_lower_limit>
            <ci_upper_limit>1.665</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ITT WT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.6145</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.084</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.792</ci_lower_limit>
            <ci_upper_limit>1.483</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score</title>
        <description>QLQ-LC13 Quality-of-Life Questionnaire Lung Cancer Module incorporates one multiple-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998).</description>
        <time_frame>Baseline up to approximately 29 months</time_frame>
        <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score</title>
          <description>QLQ-LC13 Quality-of-Life Questionnaire Lung Cancer Module incorporates one multiple-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998).</description>
          <population>Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cough in Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="21.0" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea in Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="5.6" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="6.3" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest Pain in Teff-high WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="22.2" lower_limit="22.2" upper_limit="NA">Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O3" value="18.4" lower_limit="18.4" upper_limit="NA">Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm and/or Shoulder Pain in Teff-high WT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="18.3" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="19.5" lower_limit="12.5" upper_limit="NA">Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="12.7" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough in ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="356"/>
                    <count group_id="O3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="21.0" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea in ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="356"/>
                    <count group_id="O3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="9.7" upper_limit="NA">Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="10.0" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm and/or Shoulder Pain in ITT-WT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="356"/>
                    <count group_id="O3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="18.3" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="19.5" lower_limit="15.2" upper_limit="NA">Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain in Chest in ITT-WT Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="356"/>
                    <count group_id="O3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="22.2" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="18.4" upper_limit="NA">Value is not available due to an insufficient number of participants with the event.&#xD;
Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Cough for Teff-high WT ITT population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.8816</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.041</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.614</ci_lower_limit>
            <ci_upper_limit>1.763</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Cough for Teff-high WT ITT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.2995</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.741</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.419</ci_lower_limit>
            <ci_upper_limit>1.309</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dyspnea in Teff-high WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.7578</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.936</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.616</ci_lower_limit>
            <ci_upper_limit>1.422</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dyspnea in Teff-high WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.8470</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.041</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.694</ci_lower_limit>
            <ci_upper_limit>1.560</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain in Chest in Teff-high WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.1289</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.659</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.383</ci_lower_limit>
            <ci_upper_limit>1.133</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain in Chest in Teff-high WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.2381</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.729</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.430</ci_lower_limit>
            <ci_upper_limit>1.235</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Arm and/or Shoulder Pain in Teff-high WT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.7163</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.090</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.685</ci_lower_limit>
            <ci_upper_limit>1.732</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Arm and/or Shoulder Pain in Teff-high WT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.1502</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.693</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.420</ci_lower_limit>
            <ci_upper_limit>1.145</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Cough in ITT-WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.9568</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.713</ci_lower_limit>
            <ci_upper_limit>1.430</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Cough in ITT-WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.5377</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.891</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.619</ci_lower_limit>
            <ci_upper_limit>1.284</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dyspnea in ITT-WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.4012</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.893</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.685</ci_lower_limit>
            <ci_upper_limit>1.163</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dyspnea in ITT-WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.7149</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.050</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.809</ci_lower_limit>
            <ci_upper_limit>1.363</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Arm and/or Shoulder Pain in ITT-WT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.7126</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.057</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.786</ci_lower_limit>
            <ci_upper_limit>1.422</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Arm and/or Shoulder Pain in ITT-WT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.6053</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.921</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.675</ci_lower_limit>
            <ci_upper_limit>1.258</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain in Chest in ITT-WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.3134</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.829</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.576</ci_lower_limit>
            <ci_upper_limit>1.194</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain in Chest in ITT-WT Population</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Stratified Analysis</non_inferiority_desc>
            <p_value>0.6115</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.910</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.633</ci_lower_limit>
            <ci_upper_limit>1.309</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale</title>
        <description>The SILC (Symptoms in Lung Cancer) scale was used to assess patient-reported severity of lung cancer symptoms (chest pain, dyspnea, and cough). The SILC scale is a 9-item content validated self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a symptom severity score. The SILC questionnaire comprises three individual symptoms (dyspnea, cough, chest pain) and are scored at the individual symptom level, thus have a dyspnea score, chest pain score, and cough score. Each individual symptom score is calculated as the average of responses for the symptom items [e.g. Chest Pain Score=mean (item 1; item 2)]. An increase in score is suggestive of a worsening in symptomology (i.e. frequency or severity). A score change of ≥0.3 points for the dyspnea and cough symptom scores is considered to be clinically significant; whereas a score change of ≥0.5 points for the chest pain score is considered to be clinically significant.</description>
        <time_frame>Baseline up to approximately 29 months</time_frame>
        <population>No participants were analyzed due to psychometric properties within the NSCLC population are still being determined. Due to quality issues data not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale</title>
          <description>The SILC (Symptoms in Lung Cancer) scale was used to assess patient-reported severity of lung cancer symptoms (chest pain, dyspnea, and cough). The SILC scale is a 9-item content validated self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a symptom severity score. The SILC questionnaire comprises three individual symptoms (dyspnea, cough, chest pain) and are scored at the individual symptom level, thus have a dyspnea score, chest pain score, and cough score. Each individual symptom score is calculated as the average of responses for the symptom items [e.g. Chest Pain Score=mean (item 1; item 2)]. An increase in score is suggestive of a worsening in symptomology (i.e. frequency or severity). A score change of ≥0.3 points for the dyspnea and cough symptom scores is considered to be clinically significant; whereas a score change of ≥0.5 points for the chest pain score is considered to be clinically significant.</description>
          <population>No participants were analyzed due to psychometric properties within the NSCLC population are still being determined. Due to quality issues data not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <description>Percentage of participants with at least one adverse event.</description>
        <time_frame>Baseline up to data cutoff date 7 December 2020 (up to approximately 68 months)</time_frame>
        <population>Safety population included all treated patients, defined as randomized patients who received any amount of any component of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events</title>
          <description>Percentage of participants with at least one adverse event.</description>
          <population>Safety population included all treated patients, defined as randomized patients who received any amount of any component of study treatment.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0"/>
                    <measurement group_id="O2" value="98.2"/>
                    <measurement group_id="O3" value="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab</title>
        <time_frame>Baseline up to approximately 29 months</time_frame>
        <population>The baseline ADA-evaluable population for each study treatment included patients who had a baseline ADA result. The post-baseline ADA-evaluable population for each study treatment included patients who had at least one post-baseline ADA result and had received at least on dose of that study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab</title>
          <population>The baseline ADA-evaluable population for each study treatment included patients who had a baseline ADA result. The post-baseline ADA-evaluable population for each study treatment included patients who had at least one post-baseline ADA result and had received at least on dose of that study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) of Atezolizumab in Arm A and Arm B</title>
        <description>The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.</description>
        <time_frame>Day 1 of Cycle 1 and 3 (Cycle length=21 days)</time_frame>
        <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) of Atezolizumab in Arm A and Arm B</title>
          <description>The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.</description>
          <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410" spread="157"/>
                    <measurement group_id="O2" value="414" spread="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="498" spread="160"/>
                    <measurement group_id="O2" value="540" spread="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Arm A and Arm B</title>
        <time_frame>Day 21 of Cycles 1, 2 3, and 7 (Cycle length=21 days)</time_frame>
        <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Arm A and Arm B</title>
          <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
                <count group_id="O2" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="354"/>
                    <count group_id="O2" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" spread="37.7"/>
                    <measurement group_id="O2" value="80.8" spread="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="322"/>
                    <count group_id="O2" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" spread="55.7"/>
                    <measurement group_id="O2" value="130" spread="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="307"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146" spread="58.9"/>
                    <measurement group_id="O2" value="160" spread="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219" spread="89.6"/>
                    <measurement group_id="O2" value="220" spread="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations for Carboplatin in Arm A, Arm B, and Arm C</title>
        <time_frame>Predose (same day of treatment administration), 5-10 minutes before end of carboplatin infusion, 1 h after carboplatin infusion (infusion duration=15 to 30 minutes) on D1 of Cy1,3 (Cycle length=21 days)</time_frame>
        <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations for Carboplatin in Arm A, Arm B, and Arm C</title>
          <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cy1D1 Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Predose of Cycle 1 Day 1 administration of Carboplatin.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Predose of Cycle 1 Day 1 administration of Carboplatin.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Predose of Cycle 1 Day 1 administration of Carboplatin.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cy1D1 Before End of Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18300" spread="9610"/>
                    <measurement group_id="O2" value="18300" spread="11900"/>
                    <measurement group_id="O3" value="17200" spread="9860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cy1D1 After Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11700" spread="5570"/>
                    <measurement group_id="O2" value="13900" spread="14300"/>
                    <measurement group_id="O3" value="10100" spread="5320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cy2D21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" spread="82.9"/>
                    <measurement group_id="O2" value="190" spread="113"/>
                    <measurement group_id="O3" value="143" spread="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cy3D1 Before End of Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20900" spread="8330"/>
                    <measurement group_id="O2" value="18700" spread="9410"/>
                    <measurement group_id="O3" value="20600" spread="12900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cy3D1 After Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11700" spread="6990"/>
                    <measurement group_id="O2" value="12200" spread="7480"/>
                    <measurement group_id="O3" value="10400" spread="4150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations for Paclitaxel in Arm A, Arm B, and Arm C</title>
        <time_frame>Predose (same day of treatment administration), 5-10 minutes before end of paclitaxel infusion, 1 h after paclitaxel infusion (infusion duration=3 h) on D1 of Cy1,3 (Cycle length=21 days)</time_frame>
        <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Atezolizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations for Paclitaxel in Arm A, Arm B, and Arm C</title>
          <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cy1D1 Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Predose of Cycle 1 Day 1 administration of Paclitaxel.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Predose of Cycle 1 Day 1 administration of Paclitaxel.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Predose of Cycle 1 Day 1 administration of Paclitaxel.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cy1D1 Before End of Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4850" spread="2800"/>
                    <measurement group_id="O2" value="6440" spread="3640"/>
                    <measurement group_id="O3" value="5560" spread="2590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cy1D1 After Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2300" spread="2790"/>
                    <measurement group_id="O2" value="2490" spread="3020"/>
                    <measurement group_id="O3" value="1980" spread="1780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cy2D21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Mean or SD is not reported because more than half of the samples at the specified timepoint are below the limit of quantification.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Mean or SD is not reported because more than half of the samples at the specified timepoint are below the limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cy3D1 Before End Of Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5810" spread="3610"/>
                    <measurement group_id="O2" value="7810" spread="4510"/>
                    <measurement group_id="O3" value="7810" spread="5160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cy3D1 After Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1800" spread="1660"/>
                    <measurement group_id="O2" value="2990" spread="5830"/>
                    <measurement group_id="O3" value="1930" spread="1380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Bevacizumab in Arm B and Arm C</title>
        <time_frame>Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length=21 days)</time_frame>
        <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Bevacizumab in Arm B and Arm C</title>
          <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329" spread="129"/>
                    <measurement group_id="O2" value="323" spread="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413" spread="126"/>
                    <measurement group_id="O2" value="430" spread="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmin of Bevacizumab in Arm B and Arm C</title>
        <time_frame>Cycle 1 Day 1 and Cycle 2 Day 21 (Cycle length=21 days)</time_frame>
        <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)</title>
            <description>Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Bevacizumab+Paclitaxel+Carboplatin)</title>
            <description>Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin of Bevacizumab in Arm B and Arm C</title>
          <population>The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="325"/>
                    <count group_id="O2" value="348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Predose of Cycle 1 Day 1 administration of Bevacizumab.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Predose of Cycle 1 Day 1 administration of Bevacizumab.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="280"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" spread="50.9"/>
                    <measurement group_id="O2" value="90.4" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first study drug to the data cutoff date 7 December 2020 (up to approximately 68 months)</time_frame>
      <desc>The safety population included all treated participants, defined as randomized participants who received any amount of any component of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm C (Bev+CP)</title>
          <description>Bevacizumab+Paclitaxel+Carboplatin</description>
        </group>
        <group group_id="E2">
          <title>Arm B (Atezo+Bev+CP)</title>
          <description>Atezolizumab+Bevacizumab+Paclitaxel+Carboplatin</description>
        </group>
        <group group_id="E3">
          <title>Arm A (Atezo+CP)</title>
          <description>Atezolizumab+Paclitaxel+Carboplatin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="311" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="285" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="293" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="170" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="394"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="393"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BONE MARROW FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="394"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="393"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MYELOSUPPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SPONTANEOUS HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>AUTOIMMUNE MYOCARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ADRENOCORTICAL INSUFFICIENCY ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DIABETES INSIPIDUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPOPHYSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SECONDARY ADRENOCORTICAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>OPTIC NEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="393"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>GLOSSODYNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INTESTINAL ANGINA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INTESTINAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL FOOD IMPACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="393"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CATHETER SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="394"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>COMPLICATION ASSOCIATED WITH DEVICE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INFUSION SITE EXTRAVASATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="393"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HEPATOMEGALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HEPATOTOXICITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BONE ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CHRONIC SINUSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ENTERITIS INFECTIOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>FEBRILE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS CLOSTRIDIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HEPATITIS A</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HEPATITIS C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INFECTIOUS PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PARAINFLUENZAE VIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PAROTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="394"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="393"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ADENOVIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PROSTATIC ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PYOPNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION FUNGAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SALMONELLOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SCROTAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="394"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>VASCULAR DEVICE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INFUSION RELATED REACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>STERNAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>WOUND COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BLOOD LACTATE DEHYDROGENASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL CONDITION ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="394"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="393"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>COMPARTMENT SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>OSTEOLYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE NECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SPINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>VERTEBRAL FORAMINAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ADENOCARCINOMA GASTRIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BLADDER TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MARROW HYPERPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MENINGIOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>METASTASES TO MENINGES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>TUMOUR PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>TUMOUR PSEUDOPROGRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DYSAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>FOCAL DYSCOGNITIVE SEIZURES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="393"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DELUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>GLOMERULONEPHROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PRERENAL FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RENAL INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>TUBULOINTERSTITIAL NEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>URINARY TRACT OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BRONCHOSTENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="393"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>IMMUNE-MEDIATED PNEUMONITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="393"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="394"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="393"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PULMONARY NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ERYTHEMA MULTIFORME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PEMPHIGOID</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>VERTEBROPLASTY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DIABETIC VASCULAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>EMBOLISM VENOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>LYMPHOEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="381" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="375" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="385" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="124" subjects_affected="104" subjects_at_risk="394"/>
                <counts group_id="E2" events="134" subjects_affected="116" subjects_at_risk="393"/>
                <counts group_id="E3" events="183" subjects_affected="146" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="394"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="393"/>
                <counts group_id="E3" events="35" subjects_affected="20" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="107" subjects_affected="70" subjects_at_risk="394"/>
                <counts group_id="E2" events="111" subjects_affected="72" subjects_at_risk="393"/>
                <counts group_id="E3" events="85" subjects_affected="60" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="64" subjects_affected="45" subjects_at_risk="394"/>
                <counts group_id="E2" events="74" subjects_affected="53" subjects_at_risk="393"/>
                <counts group_id="E3" events="78" subjects_affected="49" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="394"/>
                <counts group_id="E2" events="56" subjects_affected="50" subjects_at_risk="393"/>
                <counts group_id="E3" events="40" subjects_affected="33" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="394"/>
                <counts group_id="E2" events="48" subjects_affected="36" subjects_at_risk="393"/>
                <counts group_id="E3" events="36" subjects_affected="29" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="115" subjects_affected="92" subjects_at_risk="394"/>
                <counts group_id="E2" events="151" subjects_affected="122" subjects_at_risk="393"/>
                <counts group_id="E3" events="128" subjects_affected="103" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="133" subjects_affected="98" subjects_at_risk="394"/>
                <counts group_id="E2" events="221" subjects_affected="125" subjects_at_risk="393"/>
                <counts group_id="E3" events="137" subjects_affected="82" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="394"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="393"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="394"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="393"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="177" subjects_affected="124" subjects_at_risk="394"/>
                <counts group_id="E2" events="223" subjects_affected="149" subjects_at_risk="393"/>
                <counts group_id="E3" events="210" subjects_affected="130" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="394"/>
                <counts group_id="E2" events="73" subjects_affected="54" subjects_at_risk="393"/>
                <counts group_id="E3" events="27" subjects_affected="23" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="105" subjects_affected="67" subjects_at_risk="394"/>
                <counts group_id="E2" events="99" subjects_affected="71" subjects_at_risk="393"/>
                <counts group_id="E3" events="92" subjects_affected="69" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="107" subjects_affected="80" subjects_at_risk="394"/>
                <counts group_id="E2" events="143" subjects_affected="84" subjects_at_risk="393"/>
                <counts group_id="E3" events="127" subjects_affected="76" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="394"/>
                <counts group_id="E2" events="37" subjects_affected="35" subjects_at_risk="393"/>
                <counts group_id="E3" events="44" subjects_affected="38" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="125" subjects_affected="107" subjects_at_risk="394"/>
                <counts group_id="E2" events="157" subjects_affected="137" subjects_at_risk="393"/>
                <counts group_id="E3" events="129" subjects_affected="111" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="394"/>
                <counts group_id="E2" events="43" subjects_affected="27" subjects_at_risk="393"/>
                <counts group_id="E3" events="27" subjects_affected="20" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="394"/>
                <counts group_id="E2" events="42" subjects_affected="38" subjects_at_risk="393"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="394"/>
                <counts group_id="E2" events="42" subjects_affected="35" subjects_at_risk="393"/>
                <counts group_id="E3" events="33" subjects_affected="29" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="394"/>
                <counts group_id="E2" events="31" subjects_affected="26" subjects_at_risk="393"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="44" subjects_affected="34" subjects_at_risk="394"/>
                <counts group_id="E2" events="88" subjects_affected="67" subjects_at_risk="393"/>
                <counts group_id="E3" events="66" subjects_affected="53" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="394"/>
                <counts group_id="E2" events="37" subjects_affected="28" subjects_at_risk="393"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="394"/>
                <counts group_id="E2" events="34" subjects_affected="27" subjects_at_risk="393"/>
                <counts group_id="E3" events="50" subjects_affected="31" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="394"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="393"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="394"/>
                <counts group_id="E2" events="56" subjects_affected="37" subjects_at_risk="393"/>
                <counts group_id="E3" events="43" subjects_affected="24" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="37" subjects_affected="28" subjects_at_risk="394"/>
                <counts group_id="E2" events="57" subjects_affected="35" subjects_at_risk="393"/>
                <counts group_id="E3" events="51" subjects_affected="37" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="394"/>
                <counts group_id="E2" events="45" subjects_affected="30" subjects_at_risk="393"/>
                <counts group_id="E3" events="26" subjects_affected="22" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="394"/>
                <counts group_id="E2" events="48" subjects_affected="30" subjects_at_risk="393"/>
                <counts group_id="E3" events="29" subjects_affected="22" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="72" subjects_affected="34" subjects_at_risk="394"/>
                <counts group_id="E2" events="87" subjects_affected="49" subjects_at_risk="393"/>
                <counts group_id="E3" events="64" subjects_affected="33" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="76" subjects_affected="44" subjects_at_risk="394"/>
                <counts group_id="E2" events="84" subjects_affected="57" subjects_at_risk="393"/>
                <counts group_id="E3" events="59" subjects_affected="41" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="46" subjects_affected="42" subjects_at_risk="394"/>
                <counts group_id="E2" events="56" subjects_affected="52" subjects_at_risk="393"/>
                <counts group_id="E3" events="32" subjects_affected="29" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="39" subjects_affected="20" subjects_at_risk="394"/>
                <counts group_id="E2" events="42" subjects_affected="26" subjects_at_risk="393"/>
                <counts group_id="E3" events="27" subjects_affected="17" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="102" subjects_affected="86" subjects_at_risk="394"/>
                <counts group_id="E2" events="157" subjects_affected="119" subjects_at_risk="393"/>
                <counts group_id="E3" events="129" subjects_affected="100" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="394"/>
                <counts group_id="E2" events="42" subjects_affected="33" subjects_at_risk="393"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="394"/>
                <counts group_id="E2" events="47" subjects_affected="36" subjects_at_risk="393"/>
                <counts group_id="E3" events="30" subjects_affected="24" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="394"/>
                <counts group_id="E2" events="76" subjects_affected="55" subjects_at_risk="393"/>
                <counts group_id="E3" events="49" subjects_affected="38" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="394"/>
                <counts group_id="E2" events="32" subjects_affected="23" subjects_at_risk="393"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="155" subjects_affected="102" subjects_at_risk="394"/>
                <counts group_id="E2" events="227" subjects_affected="130" subjects_at_risk="393"/>
                <counts group_id="E3" events="175" subjects_affected="105" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="50" subjects_affected="43" subjects_at_risk="394"/>
                <counts group_id="E2" events="67" subjects_affected="57" subjects_at_risk="393"/>
                <counts group_id="E3" events="70" subjects_affected="51" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="394"/>
                <counts group_id="E2" events="33" subjects_affected="23" subjects_at_risk="393"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="394"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="393"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="81" subjects_affected="53" subjects_at_risk="394"/>
                <counts group_id="E2" events="118" subjects_affected="69" subjects_at_risk="393"/>
                <counts group_id="E3" events="104" subjects_affected="67" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="43" subjects_affected="32" subjects_at_risk="394"/>
                <counts group_id="E2" events="63" subjects_affected="50" subjects_at_risk="393"/>
                <counts group_id="E3" events="52" subjects_affected="45" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="31" subjects_affected="26" subjects_at_risk="394"/>
                <counts group_id="E2" events="34" subjects_affected="27" subjects_at_risk="393"/>
                <counts group_id="E3" events="39" subjects_affected="28" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="394"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="393"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="65" subjects_affected="53" subjects_at_risk="394"/>
                <counts group_id="E2" events="87" subjects_affected="70" subjects_at_risk="393"/>
                <counts group_id="E3" events="49" subjects_affected="41" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" events="77" subjects_affected="67" subjects_at_risk="394"/>
                <counts group_id="E2" events="105" subjects_affected="92" subjects_at_risk="393"/>
                <counts group_id="E3" events="117" subjects_affected="104" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="50" subjects_affected="44" subjects_at_risk="394"/>
                <counts group_id="E2" events="59" subjects_affected="53" subjects_at_risk="393"/>
                <counts group_id="E3" events="42" subjects_affected="37" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" events="59" subjects_affected="54" subjects_at_risk="394"/>
                <counts group_id="E2" events="73" subjects_affected="65" subjects_at_risk="393"/>
                <counts group_id="E3" events="65" subjects_affected="58" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="394"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="393"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="394"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="393"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="41" subjects_affected="38" subjects_at_risk="394"/>
                <counts group_id="E2" events="43" subjects_affected="42" subjects_at_risk="393"/>
                <counts group_id="E3" events="56" subjects_affected="50" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="81" subjects_affected="63" subjects_at_risk="394"/>
                <counts group_id="E2" events="128" subjects_affected="80" subjects_at_risk="393"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="94" subjects_affected="77" subjects_at_risk="394"/>
                <counts group_id="E2" events="107" subjects_affected="86" subjects_at_risk="393"/>
                <counts group_id="E3" events="99" subjects_affected="82" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="394"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="393"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="66" subjects_affected="60" subjects_at_risk="394"/>
                <counts group_id="E2" events="81" subjects_affected="67" subjects_at_risk="393"/>
                <counts group_id="E3" events="107" subjects_affected="86" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="108" subjects_affected="86" subjects_at_risk="394"/>
                <counts group_id="E2" events="89" subjects_affected="67" subjects_at_risk="393"/>
                <counts group_id="E3" events="22" subjects_affected="17" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="394"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="393"/>
                <counts group_id="E3" events="27" subjects_affected="16" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="394"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="393"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="183" subjects_affected="180" subjects_at_risk="394"/>
                <counts group_id="E2" events="195" subjects_affected="188" subjects_at_risk="393"/>
                <counts group_id="E3" events="182" subjects_affected="180" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="394"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="393"/>
                <counts group_id="E3" events="28" subjects_affected="24" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="394"/>
                <counts group_id="E2" events="76" subjects_affected="58" subjects_at_risk="393"/>
                <counts group_id="E3" events="72" subjects_affected="52" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="34" subjects_affected="28" subjects_at_risk="394"/>
                <counts group_id="E2" events="92" subjects_affected="72" subjects_at_risk="393"/>
                <counts group_id="E3" events="94" subjects_affected="71" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="102" subjects_affected="87" subjects_at_risk="394"/>
                <counts group_id="E2" events="149" subjects_affected="104" subjects_at_risk="393"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

